Cargando…
ALK融合基因阳性非小细胞肺癌的研究进展
The incidence of ALK gene rearrangement in non-small cell lung cancer (NSCLC) was about 3% to 5%. ALK gene inhibitors have made great breakthrough in recent years, significantly extending the survival period of patients with ALK(+) advanced NSCLC. But the majority of patients will be acquired drug r...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136995/ https://www.ncbi.nlm.nih.gov/pubmed/30201071 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.09.10 |